ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-23G13850
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Adeno Associated Virus AAV Vector Based Gene Therapy Market Research Report 2023
BUY CHAPTERS

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Research Report 2025

Code: QYRE-Auto-23G13850
Report
July 2025
Pages:84
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer Inc
NightstaRx
MeiraGTx Limited
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios BioPharmaceutical

Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size

The global market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy was valued at US$ 846 million in the year 2024 and is projected to reach a revised size of US$ 1217 million by 2031, growing at a CAGR of 5.4% during the forecast period.

Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno-Associated Virus (AAV) Vector-Based Gene Therapy.
The Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Report

Report Metric Details
Report Name Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
Accounted market size in year US$ 846 million
Forecasted market size in 2031 US$ 1217 million
CAGR 5.4%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Single-stranded AAV (ssAAV)
  • Self-complementary AAV (scAAV)
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Asklepios Biopharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market growing?

Ans: The Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market witnessing a CAGR of 5.4% during the forecast period 2025-2031.

What is the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market size in 2031?

Ans: The Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market size in 2031 will be US$ 1217 million.

Who are the main players in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market report?

Ans: The main players in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market are BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Asklepios Biopharmaceutical

What are the Application segmentation covered in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market report?

Ans: The Applications covered in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market report are Hemophilia, Ophthalmology, Lysosomal Storage Disorders, Neurological Disorders, Others

What are the Type segmentation covered in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market report?

Ans: The Types covered in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market report are Single-stranded AAV (ssAAV), Self-complementary AAV (scAAV)

Recommended Reports

AAV & Vector Markets

Gene Therapy

Viral Mediated Therapies

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Single-stranded AAV (ssAAV)
1.2.3 Self-complementary AAV (scAAV)
1.3 Market by Application
1.3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hemophilia
1.3.3 Ophthalmology
1.3.4 Lysosomal Storage Disorders
1.3.5 Neurological Disorders
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Perspective (2020-2031)
2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Trends by Region
2.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Region (2020-2025)
2.2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2026-2031)
2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Dynamics
2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Trends
2.3.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
2.3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
2.3.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Revenue
3.1.1 Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Revenue (2020-2025)
3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2020-2025)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio
3.4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2024
3.5 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Head office and Area Served
3.6 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
3.7 Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Breakdown Data by Type
4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Type (2020-2025)
4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2026-2031)
5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Breakdown Data by Application
5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Application (2020-2025)
5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2020-2031)
6.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025)
6.4 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2020-2031)
7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025)
7.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2020-2031)
8.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025)
8.4 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2020-2031)
9.2 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025)
9.4 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2020-2031)
10.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025)
10.4 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BioMarin Pharmaceutical
11.1.1 BioMarin Pharmaceutical Company Details
11.1.2 BioMarin Pharmaceutical Business Overview
11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.1.4 BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.1.5 BioMarin Pharmaceutical Recent Development
11.2 Sangamo Therapeutics
11.2.1 Sangamo Therapeutics Company Details
11.2.2 Sangamo Therapeutics Business Overview
11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.2.4 Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.2.5 Sangamo Therapeutics Recent Development
11.3 Amicus Therapeutics
11.3.1 Amicus Therapeutics Company Details
11.3.2 Amicus Therapeutics Business Overview
11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.3.4 Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.3.5 Amicus Therapeutics Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.4.4 Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.4.5 Roche Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.5.4 Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.5.5 Pfizer Recent Development
11.6 NightstaRx
11.6.1 NightstaRx Company Details
11.6.2 NightstaRx Business Overview
11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.6.4 NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.6.5 NightstaRx Recent Development
11.7 MeiraGTx
11.7.1 MeiraGTx Company Details
11.7.2 MeiraGTx Business Overview
11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.7.4 MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.7.5 MeiraGTx Recent Development
11.8 Sarepta Therapeutics
11.8.1 Sarepta Therapeutics Company Details
11.8.2 Sarepta Therapeutics Business Overview
11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.8.4 Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.8.5 Sarepta Therapeutics Recent Development
11.9 Neurocrine Biosciences
11.9.1 Neurocrine Biosciences Company Details
11.9.2 Neurocrine Biosciences Business Overview
11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.9.4 Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.9.5 Neurocrine Biosciences Recent Development
11.10 Voyager Therapeutics
11.10.1 Voyager Therapeutics Company Details
11.10.2 Voyager Therapeutics Business Overview
11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.10.4 Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.10.5 Voyager Therapeutics Recent Development
11.11 Asklepios Biopharmaceutical
11.11.1 Asklepios Biopharmaceutical Company Details
11.11.2 Asklepios Biopharmaceutical Business Overview
11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
11.11.4 Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
11.11.5 Asklepios Biopharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer Inc
NightstaRx
MeiraGTx Limited
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios BioPharmaceutical
List of Tables
 Table 1. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Single-stranded AAV (ssAAV)
 Table 3. Key Players of Self-complementary AAV (scAAV)
 Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2020-2025)
 Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2026-2031)
 Table 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends
 Table 11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
 Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
 Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
 Table 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players (2020-2025)
 Table 16. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2024)
 Table 17. Ranking of Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Headquarters and Area Served
 Table 20. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Product and Application
 Table 21. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2020-2025)
 Table 25. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Type (2026-2031)
 Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Application (2020-2025)
 Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Application (2026-2031)
 Table 31. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2026-2031) & (US$ Million)
 Table 46. BioMarin Pharmaceutical Company Details
 Table 47. BioMarin Pharmaceutical Business Overview
 Table 48. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 49. BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 50. BioMarin Pharmaceutical Recent Development
 Table 51. Sangamo Therapeutics Company Details
 Table 52. Sangamo Therapeutics Business Overview
 Table 53. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 54. Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 55. Sangamo Therapeutics Recent Development
 Table 56. Amicus Therapeutics Company Details
 Table 57. Amicus Therapeutics Business Overview
 Table 58. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 59. Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 60. Amicus Therapeutics Recent Development
 Table 61. Roche Company Details
 Table 62. Roche Business Overview
 Table 63. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 64. Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 65. Roche Recent Development
 Table 66. Pfizer Company Details
 Table 67. Pfizer Business Overview
 Table 68. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 69. Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 70. Pfizer Recent Development
 Table 71. NightstaRx Company Details
 Table 72. NightstaRx Business Overview
 Table 73. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 74. NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 75. NightstaRx Recent Development
 Table 76. MeiraGTx Company Details
 Table 77. MeiraGTx Business Overview
 Table 78. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 79. MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 80. MeiraGTx Recent Development
 Table 81. Sarepta Therapeutics Company Details
 Table 82. Sarepta Therapeutics Business Overview
 Table 83. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 84. Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 85. Sarepta Therapeutics Recent Development
 Table 86. Neurocrine Biosciences Company Details
 Table 87. Neurocrine Biosciences Business Overview
 Table 88. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 89. Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 90. Neurocrine Biosciences Recent Development
 Table 91. Voyager Therapeutics Company Details
 Table 92. Voyager Therapeutics Business Overview
 Table 93. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 94. Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 95. Voyager Therapeutics Recent Development
 Table 96. Asklepios Biopharmaceutical Company Details
 Table 97. Asklepios Biopharmaceutical Business Overview
 Table 98. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product
 Table 99. Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
 Table 100. Asklepios Biopharmaceutical Recent Development
 Table 101. Research Programs/Design for This Report
 Table 102. Key Data Information from Secondary Sources
 Table 103. Key Data Information from Primary Sources
 Table 104. Authors List of This Report


List of Figures
 Figure 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Picture
 Figure 2. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type: 2024 VS 2031
 Figure 4. Single-stranded AAV (ssAAV) Features
 Figure 5. Self-complementary AAV (scAAV) Features
 Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application: 2024 VS 2031
 Figure 8. Hemophilia Case Studies
 Figure 9. Ophthalmology Case Studies
 Figure 10. Lysosomal Storage Disorders Case Studies
 Figure 11. Neurological Disorders Case Studies
 Figure 12. Others Case Studies
 Figure 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered
 Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region: 2024 VS 2031
 Figure 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Players in 2024
 Figure 18. Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2024
 Figure 20. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2020-2031)
 Figure 22. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2020-2031)
 Figure 26. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Region (2020-2031)
 Figure 34. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2020-2031)
 Figure 42. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Country (2020-2031)
 Figure 46. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. BioMarin Pharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 50. Sangamo Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 51. Amicus Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 52. Roche Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 53. Pfizer Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 54. NightstaRx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 55. MeiraGTx Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 56. Sarepta Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 57. Neurocrine Biosciences Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 58. Voyager Therapeutics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 59. Asklepios Biopharmaceutical Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2020-2025)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global AAV Vector Gene Therapy Market Research Report 2024
Global AAV based Gene Therapy Products Market Research Report 2024
Global AAV Gene Therapy Drugs Market Research Report 2024
Global Adeno Associated Virus Vectors in Gene Therapy Market Research Report 2025
Global AAV Vector Based Gene Therapy Drugs Market Research Report 2024
Adeno Associated Virus AAV Gene Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Viral Vectors Gene Therapy Market Research Report 2025
Global AAV Gene Therapy Injection Market Research Report 2024
Global Ophthalmic AAV Gene Therapy Market Research Report 2024
Global Viral and Non viral Vector Market Research Report 2024
Global Adeno Associated Virus AAV Packaging Service Market Research Report 2024
Global Custom Adeno Associated Virus AAV Services Market Research Report 2024
Global Premade AAV Particles Market Research Report 2025
Viral Vector Production Research use Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Gene Therapy based Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Adeno Associated Virus Production Market Research Report 2024
Global Viral Vector Based Gene Therapy Market Research Report 2025
Global Gene Therapy Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031
Global AAV Transfection Reagent Market Research Report 2024
Gene Therapy Viral Vector and Plasmid DNA Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Hepatitis B Virus Core Antibody Diagnostic Kits Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-21N6899
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Pediatric Vaccines Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13M6952
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Poliomyelitis Vaccines Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29X7355
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Varicella Virus (Chickenpox) Vaccine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28B293
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions